HC Wainwright set a $5.00 price target on Female Health Company (The) (NASDAQ:FHCO) in a research report sent to investors on Wednesday morning. The firm currently has a buy rating on the stock.

Separately, Rodman & Renshaw began coverage on shares of Female Health Company (The) in a report on Wednesday. They issued a buy rating and a $5.00 price target on the stock.

Shares of Female Health Company (NASDAQ FHCO) traded up 6.72% during trading on Wednesday, hitting $1.27. 168,488 shares of the stock traded hands. Female Health Company has a 1-year low of $0.72 and a 1-year high of $1.65. The company’s market cap is $39.80 million. The stock has a 50-day moving average of $1.14 and a 200 day moving average of $1.06.

Female Health Company (The) (NASDAQ:FHCO) last announced its quarterly earnings results on Tuesday, May 9th. The company reported ($0.06) earnings per share (EPS) for the quarter. Female Health Company (The) had a negative return on equity of 12.51% and a negative net margin of 29.27%. The firm had revenue of $2.41 million during the quarter. On average, equities research analysts predict that Female Health Company will post $0.15 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This news story was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/hc-wainwright-analysts-give-female-health-company-the-nasdaqfhco-a-5-00-price-target/1462633.html.

In other news, insider Mitchell Shuster Steiner purchased 55,000 shares of the stock in a transaction dated Monday, June 12th. The shares were purchased at an average cost of $1.27 per share, with a total value of $69,850.00. Following the completion of the acquisition, the insider now owns 645,502 shares in the company, valued at approximately $819,787.54. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Elgar Peerschke purchased 50,000 shares of the stock in a transaction dated Friday, June 9th. The stock was purchased at an average cost of $1.25 per share, for a total transaction of $62,500.00. Following the completion of the acquisition, the director now owns 145,520 shares of the company’s stock, valued at approximately $181,900. The disclosure for this purchase can be found here. Over the last three months, insiders bought 230,569 shares of company stock worth $266,867. Insiders own 10.90% of the company’s stock.

Female Health Company (The) Company Profile

The Female Health Company is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. The Company is engaged in the development, manufacture and marketing of consumer healthcare products. The Company has three divisions: Pharmaceutical and Devices, Consumer Health Products and Public Sector.

Receive News & Ratings for Female Health Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Female Health Company (The) and related companies with Analyst Ratings Network's FREE daily email newsletter.